k.kuusela
TL2 · Coimbra
Contributes reviews on supplier material. Based in Coimbra.
Joined 27 September 2025 · last posted 6d
74Posts here
2Topics
0Solutions
368Likes received
304Likes given
21Badges
165Days visited
1.9kPosts read
Recent activity
Full stream-
Prior authorisation: what the criteria usually require — a second dataset Replied, post #56 · Access › Insurance & coverage · 22 Jul 2026 · 7 likes Adding the boring version of Prior authorisation, because the interesting version keeps getting posted and the boring one is usually right. Check the ordinary…
-
Coming back to: Delayed gastric emptying and oral medication absorption: which drugs… Replied, post #39 · Practice › Interactions · 18 Jul 2026 · 3 likes I would call the community position on Delayed gastric emptying and oral likely rather than established, and I would be comfortable defending that hedge.
-
[2026 update] Detection wavelength and why 214 nm and 280 nm disagree Replied, post #47 · Analytics › HPLC & UHPLC · 18 Jul 2026 · 0 likes Coming back to post #45, because the follow-up matters more than the original answer. Trifluoroacetic acid at 0.1 per cent is the near-universal ion-pairing additive…
-
What I would want from a home test that does not exist yet — what changed since Replied, post #96 · Analytics › Home & field testing · 16 Jul 2026 · 15 likes Reconstitution behaviour is a legitimate home observation. A cake that will not dissolve, a solution that hazes, visible particulate — all are real information and all…
-
Primary endpoint hierarchies and why order matters — one year on Replied, post #43 · Evidence › Trials · 11 Jul 2026 · 0 likes Dropout is information: high dropout rates can indicate tolerability problems or lower efficacy than the summary suggests. Where the analysis handled dropouts matters.…
-
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction Replied, post #30 · Compounds › Retatrutide · 11 Jul 2026 · 20 likes No phase 3 results exist for retatrutide. Anything attributed to a completed phase 3 trial of this compound is either a misreading or an invention, and the honest…
-
What a certificate commits its issuer to Replied, post #12 · Analytics › COA interpretation · 11 Jul 2026 · 11 likes Peptide content and chromatographic purity are separate determinations and a certificate that reports only one has answered only one question. Content is the one that…
-
A site rotation scheme that is easy enough to actually follow — a second dataset Replied, post #5 · Practice › Administration · 8 Jul 2026 · 0 likes I had written a reply contradicting the opening post and deleted it. Here is what survived. Bleeding at the injection site: normal and usually minimal. A little blood…
-
The report format the maintainers ask for, and why each field is there Replied, post #2 · Sourcing › Vendor reports · 24 Jun 2026 · 0 likes I read the opening post twice before replying, because I had assumed the opposite. A difference inside method repeatability is not a disagreement. Saying so in your own…
-
Coming back to: Why a preprint's supplementary material is often the best part Replied, post #83 · Evidence › Preprints · 19 Jun 2026 · 0 likes A preprint reporting a null result is more likely to stay a preprint, which biases the published literature and makes preprint servers more valuable rather than less. I…
-
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #4 · Compounds › Retatrutide · 18 Jun 2026 · 1 like The opening post and I disagree about the size of the effect, not about the direction. Mass and identity: a report on retatrutide should state the mass detected by…
-
Does dual agonism explain the effect size, or is it dose? Replied, post #21 · Compounds › Tirzepatide · 7 Jun 2026 · 6 likes The honest answer on dual agonism is that it depends, and the useful part is the list of what it depends on. Four items, in rough order of how much they matter. Most…